Association of immunotherapy duration with overall survival in advanced non–small cell lung cancer – this study is being released to coincide with a poster presentation at the 2023 ASCO annual meeting

JAMA Oncology

2023-06-04

(Press-News.org) About The Study: The findings of this study provide reassurance that for patients with advanced non–small cell lung cancer whose disease is still responding to immune checkpoint inhibitor therapy at two years, stopping therapy and monitoring rather than continuing immunotherapy indefinitely is a reasonable strategy with sustained clinical benefit.

Authors: Lova Sun, M.D., M.S.C.E., of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamaoncol.2023.1891)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Media advisory: This study is being released to coincide with a poster presentation at the 2023 ASCO Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2023.1891?guestAccessKey=b6d4fbbf-d578-4e83-b9f8-3f8ffd53b54b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060423

END

ELSE PRESS RELEASES FROM THIS DATE:

The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

2023-06-03

Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data of the STRO-002-GM1 global phase I study* show promise of FolRα-targeting antibody drug conjugate (ADC) luveltamab tazevibulin in patients with recurrent FolRα-expressing epithelial ovarian cancer. 80% of patients included in this study presented with FolRα expression levels higher than 25%. The overall response rate among these patients was 43.8% in the dose expansion cohort, with a median duration of response ...

Carbon-based stimuli-responsive nanomaterials: classification and application

2023-06-03

Carbon-based stimuli-responsive nanomaterials are gaining much attention due to their versatility, including disease diagnosis and treatment. They work under endogenous (pH, temperature, enzyme, and redox) or exogenous (temperature, light, magnetic field, ultrasound) stimuli. Carbon-based stimuli-responsive nanomaterials can be used as smart materials with dynamically tunable physicochemical properties in response to changes in internal or external environmental stimuli. Their diverse combinations of nanostructures and molecular designs, as well as functional ...

ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer

2023-06-03

ABSTRACT: 4008 CHICAGO ― HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer (BTC), researchers from The University of Texas MD Anderson Cancer Center reported at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The study results also were published today in The Lancet Oncology. In the first cohort of the global Phase II HERIZON-BTC-01 trial, which included 80 patients with HER2-positive tumors, the confirmed objective response rate (cORR) was 41% with a median duration of response (DOR) of 12.9 months at a median follow-up of 12.4 months. ...

Children with drug-resistant epilepsy live longer after cranial surgery

2023-06-03

Survival rate beyond 10 years in children with drug-resistant epilepsy (DRE) was highest after cranial epilepsy surgery and lowest when treated only with antiseizure medications, according to a study published in The Lancet Child and Adolescent Health. This large, retrospective study was the first to compare long-term survival in children with DRE among cohorts treated with medications only, vagus nerve stimulation plus medications, and cranial epilepsy surgery plus medications. Results show that risk of early death was reduced by over 80 percent after surgery and by 40 percent after ...

Can movie reviews predict box office success?

2023-06-03

When one thinks of movie reviews, one might see them as harbingers of success or failure at the box office. Some researchers have previously found that both positive and negative reviews correlate to box office revenues, and the effect of negative reviews diminishes over time. However, researchers at the University of California, Davis, suggest that is not the case. Researchers analyzed pre-release commentary and opening weekend box office revenue, turning the impact of movie reviews on its head and revealing an unexpected harbinger of failure phenomenon in the movie industry. The study, ...

For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising results

2023-06-03

Bile duct cancers are uncommon and aggressive types of gastrointestinal cancer. They include cholangiocarcinomas, which can form inside or outside of the liver, as well as cancers of the gallbladder, and are highly likely to cause serious disease or prove fatal. Bile duct cancers affect the biliary tract, which consists of organs and ducts that make and store bile and release it into the small intestine. They are known as “silent” cancers, because there are usually no symptoms until they reach later stages. Surgery can be effective if bile duct cancer is caught early, ...

Startups to unveil cutting-edge point-of-care technologies at Boston medtech event

2023-06-02

June 2, 2023 Contact: Emily Gowdey-Backus, 978-934-3369 or Emily_GowdeyBackus@uml.edu Nancy Cicco, 978-934-4944 or Nancy_Cicco@uml.edu Startups to unveil cutting-edge point-of-care technologies at Boston medtech event Medtech and life sciences entrepreneurs and investors forging the future of health care will come together Tuesday, June 6, to showcase pioneering technologies and grow the region’s medtech ecosystem. The 2023 Point of Care Showcase and Pitch Event will be a free, in-person program beginning at 2 p.m. at Mintz, 1 Financial Center, 40th Floor, Boston, to introduce ...

Weigh a quasar’s galaxy with precision

2023-06-02

A team of researchers from EPFL have found a way to use the phenomenon of strong gravitational lensing to determine with precision – about 3 times more precise than any other technique – the mass of a galaxy containing a quasar, as well as their evolution in cosmic time. Knowing the mass of quasar host galaxies provides insight into the evolution of galaxies in the early universe, for building scenarios of galaxy formation and black hole development. The results are published in Nature ...

Genetic variants may affect treatment response to commonly prescribed type 2 diabetes medication

2023-06-02

BOSTON – Various medications can be prescribed to lower blood sugar levels in individuals at high risk for developing type 2 diabetes, but it’s often unclear which patients will benefit most from which drugs. In a study published in Diabetologia, investigators at Massachusetts General Hospital (MGH), founding member of Mass General Brigham (MGB), identified genetic variants associated with response to two such drugs: metformin and glipizide. The findings may help personalize ...

UC Davis C-STEM trains Redlands teachers on bringing computer science into math

2023-06-02

Twenty-five teachers from Redlands Unified School District in southern California recently completed training in integrating computer science into math education through a joint program offered by the University of California, Davis, and UC Riverside Extension. The Joint Computer Science Supplementary Teaching Credential Authorization Program has helped Redlands address gaps in student opportunity and achievement, and teachers’ skills. “Improving math instruction for student success is the most challenging task in education. Redlands partnered with UC Davis to make math instruction with ...